Brind.
From Glenmark's Joint Venture Files IND for Solid Tumor Drug with FDA

How could Glenmark's IND application for solid tumour drug affect the Center for Drug Evaluation and Research?

Likely What happens if… A possibility worth considering, not a forecast.

CDER must review Glenmark's new cancer drug application for clinical trials. The submission of the Investigational New Drug (IND) application for ISB 2301 requires the U.S. Food and Drug Administration (FDA) to initiate a regulatory review. As a division of the FDA, the Center for Drug Evaluation and Research (CDER) is responsible for evaluating this drug candidate. The review will assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of ISB 2301, which is designed to target solid tumours. This review is necessary before the company can proceed with planned Phase I clinical trials in 2027.

Reported by 1 independent outlet Written Friday
Effect
Mixed
How direct
Brind's reasoning
When
Within weeks
The story
No new developments lately

How it reaches Center for Drug Evaluation and Research

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • IGI submitted an IND application to the US FDA for ISB 2301.business-standard.com
  • ISB 2301 is a pentaspecific molecule designed to target solid tumours.business-standard.com
  • The company plans to initiate a Phase I clinical trial in 2027, subject to regulatory clearance.business-standard.com
  • Preclinical studies demonstrated favourable pharmacokinetic and tolerability profiles in non-human primates.business-standard.com

Why it matters

The IND submission is a critical step for IGI's oncology pipeline, expanding its development program beyond blood cancers into the challenging area of solid tumours. Successful progression through CDER's review would allow the company to move forward with Phase I trials, potentially bringing a first-in-class treatment to patients with advanced solid tumours.

CDER's role is central to the global drug development process, acting as the gatekeeper for new therapies entering human trials. The review process ensures that the drug candidate meets rigorous safety and efficacy standards before it can be tested in patients, which is a standard requirement for all new pharmaceutical submissions to the FDA.

What we don't know yet

  • What specific data points will CDER focus on during the review of ISB 2301?
  • What is the expected timeline for CDER to grant or deny the IND application?

What would change this answer

CDER requests additional preclinical data or modifications to the trial protocolThe review process will be extended, delaying the planned Phase I clinical trials beyond 2027.
The drug candidate ISB 2301 receives fast-track designation from the FDAThe review timeline could be significantly shortened, accelerating the path to clinical development.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.